Skip to content
10-Q

Quarterly Report

TARSUS PHARMACEUTICALS, INC. TARS

0001819790-26-000038

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 43.02M sh
Shares Diluted Q1 2026 · Mar 31, 2026 42.96M sh
Shares Diluted Q1 2026 · Mar 31, 2025 39.35M sh
Capex Q1 2026 · Mar 31, 2026 $5.82M
Capex Q1 2026 · Mar 31, 2025 $590K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$24.65M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$20.65M
Long Term Debt Q1 2026 · Mar 31, 2026 $72.6M
Long Term Debt Q1 2026 · Dec 31, 2025 $72.44M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $102.19M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $183.64M
Stockholders Equity Q1 2026 · Mar 31, 2026 $348.95M
Stockholders Equity Q1 2026 · Dec 31, 2025 $343.43M
Stockholders Equity Q1 2026 · Mar 31, 2025 $342.46M
Stockholders Equity Q1 2026 · Dec 31, 2024 $224.53M
Current Liabilities Q1 2026 · Mar 31, 2026 $143.51M
Current Liabilities Q1 2026 · Dec 31, 2025 $135.7M
Total Liabilities Q1 2026 · Mar 31, 2026 $232.18M
Total Liabilities Q1 2026 · Dec 31, 2025 $218.73M
Current Assets Q1 2026 · Mar 31, 2026 $537.23M
Current Assets Q1 2026 · Dec 31, 2025 $522.78M
Total Assets Q1 2026 · Mar 31, 2026 $581.14M
Total Assets Q1 2026 · Dec 31, 2025 $562.16M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.16
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.64
Eps Basic Q1 2026 · Mar 31, 2026 −$0.16
Eps Basic Q1 2026 · Mar 31, 2025 −$0.64
Sga Expense Q1 2026 · Mar 31, 2026 $136.43M
Sga Expense Q1 2026 · Mar 31, 2025 $85M
Rd Expense Q1 2026 · Mar 31, 2026 $22.35M
Rd Expense Q1 2026 · Mar 31, 2025 $14.41M
Net Income Q1 2026 · Mar 31, 2026 −$6.97M
Net Income Q1 2026 · Mar 31, 2025 −$25.12M
Operating Income Q1 2026 · Mar 31, 2026 −$6.12M
Operating Income Q1 2026 · Mar 31, 2025 −$26.28M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $9.4M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $5.21M
Revenue Q1 2026 · Mar 31, 2026 $162.05M
Revenue Q1 2026 · Mar 31, 2025 $78.34M